Merck KGaA’s BTK Inhibitor Fails Phase III Multiple Sclerosis Studies

Germany’s Merck KGaA on Tuesday announced that its investigational BTK inhibitor evobrutinib did not meet its primary efficacy endpoint in the Phase III evolutionRMS 1 and evolutionRMS 2 trials in relapsing multiple sclerosis.